drugset / Trial / NCT03779646
Bisoprolol in DMD Early Cardiomyopathy
Phase 2/3
Unknown
42 enrolled
Peking Union Medical College Hospital
Chinese Academy of Medical Sciences · collabNational Natural Science Foundation of China · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This study aimed to use cardiac magnetic resonance imaging (CMR) to evaluate the efficacy and safety of bisoprolol therapy for boys with Duchenne muscular dystrophy(DMD) and preserved ejection fraction. On top of angiotensin-converting enzyme inhibitor (ACEI) , half of the participants will receive bisoprolol in combination, while the other half will not receive any beta-blocker.
Timeline
- Start
- 2019-01-16
- Primary completion
- 2023-07-01
- Completion
- 2024-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bisoprolol | Other / unclassified | 0.2 mg/kg | — |